The Latest Breaking News from Baxter

Baxter International has lagged behind its peers in the medical devices industry over the past three months, and analysts are cautious about the stock's prospects.

Due to Baxter International’s underperformance relative to the broader market over the past year, Wall Street analysts remain cautious about the stock’s prospects.

Baxter has underperformed the healthcare sector over the past year, and analysts are cautious about the stock’s prospects.

The medtech industry’s long-term growth is fueled by growing demand for medical devices, adoption of cutting-edge technologies, and improved efficiency. Thus, it could be ideal to buy fundamentally solid medtech stocks Baxter International (BAX), Zimmer Biomet Holdings (ZBH), and Embecta (EMBC) poised for substantial growth. Keep reading.

Baxter stock tumbled Tuesday after the medtech company agreed to sell its kidney segment to Carlyle for $3.8 billion.

As Baxter International has underperformed the broader market over the past year, Wall Street analysts remain cautious about the stock's prospects.

Growth stocks trading at lower P/E ratio than the industry average can be a suitable investment choice. Top picks now could be Cardinal Health (CAH), Baxter International (BAX), and DocuSign (DOCU). Keep reading.

‘Outrageous’ that payouts to victims in other countries are not being matched in UK, say campaigners

Vibrant colors, glossy textures, and fun shapes all celebrate the return of the 70’s at this year’s Salone del Mobile, but with a more elevated touch